Phase 1 / Phase 2TerminatedINTERVENTIONAL
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
ClinicalTrials.gov · NCT00884715 · Registry updated: 2013-09-20
- Condition / research focus
- Carcinoid Syndrome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2009-07. Completion: 2011-12 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Octreotide (drug)
Where the study takes place — 3 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Facility not reported
Iowa City, Iowa, United States
Site recruitment: Not reported - Facility not reported
Boston, Massachusetts, United States
Site recruitment: Not reported - Facility not reported
Burlington, Massachusetts, United States
Site recruitment: Not reported